Pharmaceutical Sector

A Brief History of the Modern Pharmaceutical Industry

The roots of the modern pharmaceutical sector can be traced to the chemical industry of the Rhine Valley in Europe. In the late 19th century, dye manufacturers came to the recognition that dye stuffs, and more precisely aniline and other indigo derivatives, had antiseptic properties. The commercial prospects of this discovery prompted them to develop aniline derivatives as drugs for diverse diseases. Dye stuff companies like Roche, Ciba-Geigy, and Sandoz all moved to synthetic pharmaceuticals and would soon become leaders in their field. The major pharmaceutical industries in Europe and America emerged in the late 19th and early 20th centuries.

The evolution of the pharmaceutical sector in the 20th century was shaped by three factors: scientific progress, economic changes, and the evolution of the regulatory framework. First, rapid scientific discoveries in chemistry, biology, pharmacology, and the etiology of disease accelerated the development of the pharmaceutical sector. The medical and commercial success of penicillin is often regarded as a landmark in the history of the industry that contributed to the establishment of research and development within the field.

Second, the transformation of Western capitalism greatly affected the supply of and demand for pharmaceutical products. On the production side, the advent of industrial mass production, the development of advertising, and more recently, the rise of venture capital all nurtured the growth of the industry. On the demand side, the advent of the welfare state and the development of both private and public health care systems in many industrialized countries generated lucrative opportunities for pharmaceutical firms, thereby increasing incentives for the development of new drugs.

Third, the evolution of the regulatory environment had a significant impact on the trajectory of the pharmaceutical sector. In the United States, the Food and Drug Administration (FDA) gradually tightened the regulation of drug development, most notably by requiring proof of safety and efficacy for all pharmaceutical products through clinical trials. As part of a process of international harmonization of regulation, the FDA procedures became the basis of corporate drug testing throughout the developed world. In addition, the growing complexity of regulatory requirements considerably lengthened the process of drug development. By contrast, the limitation of patent protection to 20 years boosted the development of generic medicines, thereby intensifying the race to market new drugs. These antagonistic pressures reduced the time frame under which companies could make profits. The profitability of pharmaceutical products and the high risk associated with drug development remain the key challenges to the survival of pharmaceutical firms in an increasingly competitive global market.

...